Salmonella typhi ty2 vi polysaccharide antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Salmonella typhi ty2 vi polysaccharide antigen
Accession Number
DB10803
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated / Other vaccines
Description

Salmonella typhi ty2 vi polysaccharide antigen is a vaccine that is administered intramuscularly. It is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older. The vaccine contains the purified cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain. The bacterial culture is inactivated in the medium with the capsular polysaccharides precipated from the solution.

Synonyms
  • Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Typhim ViInjection, solution25 ug/0.5mLIntramuscularSanofi Pasteur Limited1994-11-28Not applicableUs
Typhim ViSolution25 mcgIntramuscularSanofi Pasteur Limited1995-12-31Not applicableCanada
Typhim ViInjection, solution25 ug/0.5mLIntramuscularA-S Medication Solutions1994-11-28Not applicableUs
Typhim ViInjection, solution25 ug/0.5mLIntramuscularA-S Medication Solutions1994-11-28Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
VivaximSalmonella typhi ty2 vi polysaccharide antigen (25 mcg) + Hepatitis A Vaccine (160 unit)Solution; SuspensionIntramuscularSanofi Pasteur Limited2005-11-09Not applicableCanada
Categories
UNII
7194H8W3KT
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Salmonella typhi ty2 vi polysaccharide antigen.
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Salmonella typhi ty2 vi polysaccharide antigen.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Salmonella typhi ty2 vi polysaccharide antigen.
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Salmonella typhi ty2 vi polysaccharide antigen.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Salmonella typhi ty2 vi polysaccharide antigen.
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Salmonella typhi ty2 vi polysaccharide antigen.
AbituzumabThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Abituzumab.
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with Salmonella typhi ty2 vi polysaccharide antigen.
AdalimumabThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Adalimumab.
AdecatumumabThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Adecatumumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910909
AHFS Codes
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceCardiovascular Function1
0CompletedTreatmentMajor Depressive Disorder (MDD)1
1CompletedPreventionSalmonella Typhi Infection1
1CompletedTreatmentAcute Coronary Syndromes (ACS) / Inflammatory Reaction / Myocardial Infarction / Reperfusion Injury1
1RecruitingPreventionCardiovascular Disease (CVD)1
2Active Not RecruitingPreventionSalmonella Typhi Infection1
2CompletedPreventionDengue Diseases / Dengue Fever / Dengue Hemorrhagic Fever / Dengue Virus1
3CompletedPreventionBacterial Infections / Salmonella Infections / Salmonella Typhi Infection1
4Enrolling by InvitationBasic ScienceFlu caused by Influenza / Healthy Adults / Hepatitis A / Salmonella Typhi Infection1
4RecruitingDiagnosticSpecific Polysaccharide Antibody Deficiency1
Not AvailableCompletedBasic ScienceBCG Vaccination1
Not AvailableCompletedBasic ScienceTyphoid Vaccine on Sleep1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionIntramuscular25 ug/0.5mL
SolutionIntramuscular25 mcg
Solution; suspensionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:04 / Updated on October 16, 2018 08:42